Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the shares. The firm’s rating remains Outperform based on its belief that the company will be sold to Biogen (BIIB) at a significant premium, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $7 from $9 at Baird
- Cautious Outlook on SAGE Therapeutics Amid Strategic Uncertainty and Pipeline Ambiguities
- Sage Therapeutics price target lowered to $8 from $9 at Canaccord
- SAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration
- Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties